- Japan
- /
- Medical Equipment
- /
- TSE:4595
Mizuho MedyLtd First Quarter 2025 Earnings: EPS: JP¥40.79 (vs JP¥102 in 1Q 2024)
Mizuho MedyLtd (TSE:4595) First Quarter 2025 Results
Key Financial Results
- Revenue: JP¥2.65b (down 3.4% from 1Q 2024).
- Net income: JP¥777.0m (down 20% from 1Q 2024).
- Profit margin: 29% (down from 35% in 1Q 2024). The decrease in margin was primarily driven by higher expenses.
- EPS: JP¥40.79 (down from JP¥102 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mizuho MedyLtd Earnings Insights
Looking ahead, revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Japan.
Performance of the Japanese Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Mizuho MedyLtd you should know about.
If you're looking to trade Mizuho MedyLtd, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4595
Mizuho MedyLtd
Researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan.
Flawless balance sheet and good value.
Market Insights
Community Narratives

